J P Morgan Chase & Co reiterated their neutral rating on shares of Abcam Plc (LON:ABC) in a research note issued to investors on Tuesday. They currently have a GBX 864 ($11.16) price target on the stock.
ABC has been the topic of a number of other research reports. Panmure Gordon reissued a sell rating on shares of Abcam Plc in a research note on Monday. Numis Securities Ltd reissued an add rating and issued a GBX 1,116 ($14.41) target price on shares of Abcam Plc in a research note on Thursday, July 27th. Peel Hunt reissued a hold rating and issued a GBX 750 ($9.69) target price on shares of Abcam Plc in a research note on Friday, August 18th. Finally, Berenberg Bank reissued a buy rating and issued a GBX 1,100 ($14.21) target price on shares of Abcam Plc in a research note on Monday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of GBX 914 ($11.80).
Shares of Abcam Plc (ABC) opened at 1099.00 on Tuesday. The stock’s 50 day moving average price is GBX 1,052.08 and its 200-day moving average price is GBX 953.19. The company’s market cap is GBX 2.22 billion. Abcam Plc has a 12-month low of GBX 759.50 and a 12-month high of GBX 1,100.00.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/2888241/abcam-plc-abc-given-neutral-rating-at-j-p-morgan-chase-co.html.
Abcam Plc Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.